Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome

Chin Der Chen, Shee Uan Chen, Ming Yih Wu, Hong Nerng Ho, Jehn Hsiahn Yang, Yu Shih Yang

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: To determine the efficacy of IV albumin in the prevention of severe ovarian hyperstimulation syndrome (OHSS). Design: Prospective study group with historical control. Setting: University hospital-based IVF program. Patient(s): Between 1993 and 1995, 42 consecutive patients undergoing IVF-ET or tubal ET who had serum E2 levels ≤3,600 pg/mL (conversion factor to SI unit, 3.671) on the day of hCG administration and/or ≤20 oocytes retrieved were considered at high risk for severe OHSS and were selected as the control group. From December 1995 to October 1996, IV albumin was given to 30 consecutive patients who fulfilled these criteria. Intervention(s): The treatment group received IV albumin after oocyte retrieval. Main Outcome Measure: Occurrence of severe OHSS. Result(s): None of the 16 patients in the treatment group in nonconception cycles developed severe OHSS, compared with 5 (21.7%) of 23 in the control group. In conception cycles, 4 (28.6%) of 14 patients in the treatment group developed severe OHSS, compared with 9 (47.4%) of 19 in the control group. All 4 patients with multiple pregnancies in the treatment group developed severe OHSS, compared with 3 (60%) of 5 in the control group. None of the 10 patients with singleton pregnancies in the treatment group developed severe OHSS, compared with 6 (42.9%) of 14 in the control group. Conclusion(s): Intravenous albumin prevents severe OHSS in high-risk patients who did not conceive or who carried singleton pregnancies, but not in the patients with high-order pregnancies.

Original languageEnglish
Pages (from-to)287-291
Number of pages5
JournalFertility and Sterility
Volume68
Issue number2
DOIs
Publication statusPublished - Jan 1 1997
Externally publishedYes

Fingerprint

Ovarian Hyperstimulation Syndrome
Albumins
Control Groups
Pregnancy
International System of Units
Oocyte Retrieval
Therapeutics
Multiple Pregnancy
Oocytes
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • Albumin
  • IVF
  • Ovarian hyperstimulation syndrome
  • Polycystic ovaries

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. / Chen, Chin Der; Chen, Shee Uan; Wu, Ming Yih; Ho, Hong Nerng; Yang, Jehn Hsiahn; Yang, Yu Shih.

In: Fertility and Sterility, Vol. 68, No. 2, 01.01.1997, p. 287-291.

Research output: Contribution to journalArticle

Chen, Chin Der ; Chen, Shee Uan ; Wu, Ming Yih ; Ho, Hong Nerng ; Yang, Jehn Hsiahn ; Yang, Yu Shih. / Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. In: Fertility and Sterility. 1997 ; Vol. 68, No. 2. pp. 287-291.
@article{b3618df9c2264987a489ae1b02c7ce32,
title = "Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome",
abstract = "Objective: To determine the efficacy of IV albumin in the prevention of severe ovarian hyperstimulation syndrome (OHSS). Design: Prospective study group with historical control. Setting: University hospital-based IVF program. Patient(s): Between 1993 and 1995, 42 consecutive patients undergoing IVF-ET or tubal ET who had serum E2 levels ≤3,600 pg/mL (conversion factor to SI unit, 3.671) on the day of hCG administration and/or ≤20 oocytes retrieved were considered at high risk for severe OHSS and were selected as the control group. From December 1995 to October 1996, IV albumin was given to 30 consecutive patients who fulfilled these criteria. Intervention(s): The treatment group received IV albumin after oocyte retrieval. Main Outcome Measure: Occurrence of severe OHSS. Result(s): None of the 16 patients in the treatment group in nonconception cycles developed severe OHSS, compared with 5 (21.7{\%}) of 23 in the control group. In conception cycles, 4 (28.6{\%}) of 14 patients in the treatment group developed severe OHSS, compared with 9 (47.4{\%}) of 19 in the control group. All 4 patients with multiple pregnancies in the treatment group developed severe OHSS, compared with 3 (60{\%}) of 5 in the control group. None of the 10 patients with singleton pregnancies in the treatment group developed severe OHSS, compared with 6 (42.9{\%}) of 14 in the control group. Conclusion(s): Intravenous albumin prevents severe OHSS in high-risk patients who did not conceive or who carried singleton pregnancies, but not in the patients with high-order pregnancies.",
keywords = "Albumin, IVF, Ovarian hyperstimulation syndrome, Polycystic ovaries",
author = "Chen, {Chin Der} and Chen, {Shee Uan} and Wu, {Ming Yih} and Ho, {Hong Nerng} and Yang, {Jehn Hsiahn} and Yang, {Yu Shih}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0015-0282(97)81517-8",
language = "English",
volume = "68",
pages = "287--291",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome

AU - Chen, Chin Der

AU - Chen, Shee Uan

AU - Wu, Ming Yih

AU - Ho, Hong Nerng

AU - Yang, Jehn Hsiahn

AU - Yang, Yu Shih

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Objective: To determine the efficacy of IV albumin in the prevention of severe ovarian hyperstimulation syndrome (OHSS). Design: Prospective study group with historical control. Setting: University hospital-based IVF program. Patient(s): Between 1993 and 1995, 42 consecutive patients undergoing IVF-ET or tubal ET who had serum E2 levels ≤3,600 pg/mL (conversion factor to SI unit, 3.671) on the day of hCG administration and/or ≤20 oocytes retrieved were considered at high risk for severe OHSS and were selected as the control group. From December 1995 to October 1996, IV albumin was given to 30 consecutive patients who fulfilled these criteria. Intervention(s): The treatment group received IV albumin after oocyte retrieval. Main Outcome Measure: Occurrence of severe OHSS. Result(s): None of the 16 patients in the treatment group in nonconception cycles developed severe OHSS, compared with 5 (21.7%) of 23 in the control group. In conception cycles, 4 (28.6%) of 14 patients in the treatment group developed severe OHSS, compared with 9 (47.4%) of 19 in the control group. All 4 patients with multiple pregnancies in the treatment group developed severe OHSS, compared with 3 (60%) of 5 in the control group. None of the 10 patients with singleton pregnancies in the treatment group developed severe OHSS, compared with 6 (42.9%) of 14 in the control group. Conclusion(s): Intravenous albumin prevents severe OHSS in high-risk patients who did not conceive or who carried singleton pregnancies, but not in the patients with high-order pregnancies.

AB - Objective: To determine the efficacy of IV albumin in the prevention of severe ovarian hyperstimulation syndrome (OHSS). Design: Prospective study group with historical control. Setting: University hospital-based IVF program. Patient(s): Between 1993 and 1995, 42 consecutive patients undergoing IVF-ET or tubal ET who had serum E2 levels ≤3,600 pg/mL (conversion factor to SI unit, 3.671) on the day of hCG administration and/or ≤20 oocytes retrieved were considered at high risk for severe OHSS and were selected as the control group. From December 1995 to October 1996, IV albumin was given to 30 consecutive patients who fulfilled these criteria. Intervention(s): The treatment group received IV albumin after oocyte retrieval. Main Outcome Measure: Occurrence of severe OHSS. Result(s): None of the 16 patients in the treatment group in nonconception cycles developed severe OHSS, compared with 5 (21.7%) of 23 in the control group. In conception cycles, 4 (28.6%) of 14 patients in the treatment group developed severe OHSS, compared with 9 (47.4%) of 19 in the control group. All 4 patients with multiple pregnancies in the treatment group developed severe OHSS, compared with 3 (60%) of 5 in the control group. None of the 10 patients with singleton pregnancies in the treatment group developed severe OHSS, compared with 6 (42.9%) of 14 in the control group. Conclusion(s): Intravenous albumin prevents severe OHSS in high-risk patients who did not conceive or who carried singleton pregnancies, but not in the patients with high-order pregnancies.

KW - Albumin

KW - IVF

KW - Ovarian hyperstimulation syndrome

KW - Polycystic ovaries

UR - http://www.scopus.com/inward/record.url?scp=0342276127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342276127&partnerID=8YFLogxK

U2 - 10.1016/S0015-0282(97)81517-8

DO - 10.1016/S0015-0282(97)81517-8

M3 - Article

VL - 68

SP - 287

EP - 291

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 2

ER -